Advertisements

Apo Terbinafine

Quick links to important sections

Apo Terbinafine

Advertisements
Advertisements

Method of action: Antifungal Broad Spectrum

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Apo Terbinafine

Quick Facts

Property Description
Active ingredient Terbinafine Hydrochloride
Form Oral Tablet, Cream, Solution
Pharmacological class Allylamine Antifungal
General purpose To eliminate fungal infections (Antimycotic)
Origin Synthetic Compound (Generic, Apotex)

Apo Terbinafine is a generic medication containing the active ingredient Terbinafine Hydrochloride, a synthetic compound manufactured by Apotex Inc. (Canada/Australia) as an alternative to the original brand, Lamisil. Its identity is defined by its highly selective activity, distinguishing it as a primary treatment option for specific fungal diseases.

What Type of Medicine is Apo Terbinafine? (Identity and Class)

Apo Terbinafine is classified as an Antifungal agent and specifically belongs to the Allylamine Antifungal class, which is clinically recognized for its potent effect against dermatophytes, the fungi responsible for most nail and skin mycoses. The active compound, Terbinafine Hydrochloride, is a monosemantic entity with a well-defined chemical structure, often available for both prescription (oral) and over-the-counter (topical) use depending on the severity and location of the infection.

This drug's mechanism is supported by pharmacological studies that confirm its fungicidal action, meaning it actively eradicates the fungal cells rather than merely inhibiting their growth. It achieves this by interfering with the synthesis of ergosterol, a vital component required for maintaining the fungal cell membrane, leading to the pathogen's destruction.

Available Forms and General Therapeutic Purpose (Composition and Route)

The product is available in different Pharmaceutical preparations, primarily the Oral Tablet for systemic treatment and Cream or Solution for topical treatment. The composition of the product is centered on the Terbinafine Hydrochloride, which is compounded with appropriate base/vehicle excipients for the intended delivery method.

The general therapeutic purpose of utilizing Apo Terbinafine is to achieve complete resolution of fungal diseases by eliminating the causative organism. Terbinafine is effective in both topical and oral administration for treating dermatophytosis and other cutaneous mycoses. The systemic tablet formulation is generally reserved for more entrenched conditions, such as fungal infections of the nails (onychomycosis), ensuring the drug accumulates in the tissue via the bloodstream.

Regulatory References

  1. Terbinafine - StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Apo Terbinafine?

Possible Side Effects and Safety Information

The safety profile of oral Apo Terbinafine is officially documented based on regulatory classifications of adverse reactions, which are grouped by frequency and affected body systems.

Adverse Reaction Classification

Classification Common Effects System-Organ Classes
Common Headache, diarrhea, nausea, dyspepsia, rash, pruritus (itching), liver enzyme abnormalities. Gastrointestinal, Nervous System, Skin, Hepatobiliary
Very Rare Severe liver failure, severe blood disorders, severe skin reactions. Hepatobiliary, Blood and Lymphatic System, Skin and Subcutaneous Tissue

Adverse effects designated as Common are generally documented in clinical trial data, while those categorized as Very Rare are often reported in postmarketing experience.

Serious Adverse Reactions and Key Safety Constraints

Official regulatory documents emphasize the potential for severe hepatotoxicity, including cases of liver failure, which have been reported in patients both with and without pre-existing liver conditions. Consequently, the medication is contraindicated in individuals with active or chronic liver disease, and regulatory agencies advise that baseline liver function tests should be conducted for all patients prior to initiation.

Other serious but rare adverse reactions noted in official warnings include severe blood disorders (e.g., agranulocytosis) and severe skin reactions such as Stevens-Johnson Syndrome.

Time-related safety patterns have been reported for some effects; specifically, disturbances to taste and smell may be prolonged or, in rare cases, reported as permanent.

For specific populations, use in patients with renal impairment is generally not recommended due to insufficient data on safety in this group.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes the documented profile of acute Apo Terbinafine overdosage, based on reported cases involving ingestion of doses up to five grams (5 g).

Documented Overdose Manifestations

The clinical signs and symptoms reported in association with acute overdose primarily involve the gastrointestinal and nervous systems. These documented manifestations include:

  • Headache
  • Nausea and Vomiting
  • Epigastric (Stomach) Pain
  • Dizziness

Required Emergency Action

Immediate medical attention is necessary if an overdose is suspected. Government regulatory documents explicitly state that patients must contact a Poisons Information Centre for advice or seek emergency medical attention right away. Treatment is focused on supportive care, as there is no specific antidote for terbinafine overdose.

Supportive Management

Official guidance for the management of an overdose event specifies two procedural steps:

  1. Elimination of the Drug: Primarily achieved through the administration of activated charcoal.
  2. Symptomatic Supportive Therapy: Providing medical support to manage the documented symptoms (e.g., headache, vomiting) as needed.
Advertisements

Therapeutic Uses of Apo Terbinafine

What Apo Terbinafine Treats: Main Uses and Benefits

Apo Terbinafine is commonly used for its therapeutic effect against conditions characterized by periods of heightened symptoms caused by dermatophytes.

The core therapeutic domains include onychomycosis (fungal infections of the nails), tinea corporis (ringworm of the body), tinea cruris (jock itch), and tinea pedis (athlete's foot). The medication is commonly considered in contexts involving severe, extensive, or persistent fungal disease where topical treatments have been insufficient.

Treatment of Entrenched Fungal Nail Disease

This medication plays a role in managing the symptomatic burden of nail discoloration, thickening, and distortion. It supports the patient by contributing to the gradual regrowth of the nail, assisting with maintaining functional stability and comfort.

Management of Extensive Skin Mycoses

The oral form is considered relevant when pronounced symptoms—such as widespread scaling, persistent itching, and inflammation—require more comprehensive support. This helps maintain a sense of stability when symptoms are more noticeable and contributes to improved comfort during symptomatic periods.

Quick Fact: Symptom Management
Symptom Clusters Addressed Widespread scaling, persistent itching, nail distortion, and skin inflammation.
Primary Therapeutic Benefit Provides support that helps ease the overall symptom burden associated with deep-seated fungal infection.
Advertisements

Eligibility and Restrictions for Use

Apo Terbinafine tablets are not suitable for all individuals. Official regulatory documentation defines specific populations who must avoid the medicine or for whom its use is strictly limited.

Populations That Must Not Use Apo Terbinafine (Contraindications)

Classification Population/Condition
Contraindicated Individuals with a known hypersensitivity or allergy to terbinafine or any component of the formulation.
Contraindicated Patients with chronic or active liver disease due to the risk of serious hepatic adverse effects.

Populations Where Use is Not Recommended or Restricted

Classification Population/Condition
Not Recommended Patients with renal impairment (creatinine clearance le 50 mL/min) as use has not been adequately studied in this group.
Not Recommended Pregnant women and breastfeeding mothers, as the drug is excreted in human milk and clinical data on use during pregnancy is limited.
Use Not Established Pediatric patients (under 18 years of age) for the treatment of onychomycosis, as safety and efficacy have not been fully established for this indication in this population.

These constraints define the official eligibility profile by excluding patients with compromised hepatic or renal function and those at risk of severe allergic reactions, while also restricting use during key physiological states.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation confirms that oral Terbinafine Hydrochloride (Apo Terbinafine) enters into specific, documented pharmacokinetic interactions with other substances.

Interaction Classifications

Interaction Type Specific Constraint/Outcome
Formal Contraindications Use is strictly prohibited with Pimozide and Thioridazine. Use is also contraindicated in patients with Chronic or Active Liver Disease.
Enzyme Inhibition Terbinafine is documented as an inhibitor of the CYP450 2D6 isozyme, which can affect the metabolism of co-administered substrates like Desipramine.

Pharmacokinetic Exposure Modification

The official profile identifies specific substances that alter Terbinafine exposure and substances whose clearance is altered by Terbinafine.

Substances that increase Terbinafine exposure by reducing its clearance include Cimetidine (by 33%) and Fluconazole. Conversely, Rifampin dramatically increases Terbinafine clearance by 100%, significantly decreasing exposure. Terbinafine itself decreases the clearance of Caffeine by 19% and increases the clearance of Cyclosporine by 15%.

These official statements define the necessary restrictions and constraints related to co-administration, based entirely on formal regulatory data.

Advertisements

Mechanism of Action

The action of Apo Terbinafine (Terbinafine Hydrochloride) is defined by its ability to selectively target and destroy fungal cells through precise biochemical interference. It operates through two core mechanistic domains that result in fungicidal cell lysis.

Dual-Action Inhibition of Fungal Enzyme Systems

The drug functions as a noncompetitive inhibitor of squalene epoxidase, an enzyme required in the ergosterol biosynthesis pathway in fungi. This mechanism is selective, as the fungal enzyme is structurally distinct from the equivalent enzyme involved in human cholesterol synthesis.

Mechanistic Cascade Leading to Fungicidal Activity

Inhibition of the enzyme triggers a dual-action cascade: it causes a severe depletion of ergosterol (a crucial membrane component) and simultaneously results in the toxic intracellular accumulation of the precursor, squalene. This combined biochemical insult compromises the integrity and osmotic control of the fungal cell membrane, leading directly to cell rupture (lysis) and the resulting fungicidal activity.

Advertisements

Dosage and Administration Information

How to Use Apo Terbinafine: Official Administration Principles

The use of Apo Terbinafine is defined by its administration route and specific dosing regimens. The medication is available for systemic use as an oral tablet and for localized use as a topical cream or solution.

Standard Systemic Dosing and Timing

The standard regimen for systemic treatment, such as for fungal nail infections, is one 250 mg oral tablet taken once daily. This administration is flexible as the tablet may be taken with or without food. If a dose is missed, it should be taken as soon as possible, unless the next dose is due shortly, in which case the missed dose should be skipped.

Duration of Use and Population Adjustments

The required duration of oral use is predetermined by the site of infection and typically ranges from 6 to 12 weeks for onychomycosis. For instance, treatment usually lasts six weeks for fingernail infections and twelve weeks for toenail infections. For tinea infections, the duration is generally shorter, typically two to six weeks.

Specific adjustments to the standard 250 mg daily dose are required based on a patient's kidney function. The dose must be reduced by 50% (to 125 mg daily) in adults diagnosed with moderate to severe renal impairment (creatinine clearance le 50 ml/min). The medication is generally not recommended for use in patients with pre-existing liver disease.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Apo Terbinafine

Evidence for Use in Fungal Nail Infection (Onychomycosis)

The research into Apo Terbinafine (oral tablet) for fungal nail infections, or onychomycosis, was primarily based on Randomized Controlled Trials (RCTs). These studies were structured to compare the medication against a placebo or vehicle, and also against other active comparator agents. Researchers in these trials examined outcomes related to the measurement of fungal reduction, known as mycological cure. They also measured the combined result of fungal reduction combined with the monitoring of nail appearance, called complete cure. These trials focused mainly on adults who had confirmed infection caused by dermatophytes, the most common fungi in this condition.

Studies explored how the nail's clinical appearance evolved in the observed populations following treatment. Findings described patterns where measurements of full clinical clearing required observation periods extending many months past the time the medication was completed. Some trials also monitored for the rate of recurrence, tracking patients long after the treatment phase ended. Findings were mixed regarding patterns observed in comparing different methods of taking the medicine, such as continuous versus pulsed regimens.

Evidence for Use in Skin Fungal Infections (Tinea)

For skin fungal infections like athlete's foot (Tinea Pedis), jock itch (Tinea Cruris), and ringworm (Tinea Corporis), research has mainly focused on episodes where symptoms become more noticeable. Short-term, vehicle-controlled clinical trials of the topical (cream/solution) forms of the medicine examined outcomes reflecting temporary physiological imbalance in the skin, such as redness, scaling, and itching. Studies monitored the resolution of these clinical symptoms and measured mycological cure, confirming that the fungal organisms were measured as absent from the skin surface. Bioequivalence studies found that generic topical formulations were measured for equivalence against the original products in terms of how they deliver the active ingredient.

Long-Term Studies, Special Populations, and Uncertainty

Long-term follow-up studies typically included extended monitoring periods, observing patients for up to a year or longer to track the pattern of infection recurrence and nail changes over time. However, even with extended follow-up, long-term effects are not fully established regarding the durability of the initial results beyond the first two years.

Research has explored the use of the oral tablet in older adults and in patients with co-existing conditions, such as diabetes, showing patterns related to outcomes measured in these groups. However, data for certain groups remain insufficient, particularly concerning the use of the oral tablet in pregnant or breastfeeding populations. Furthermore, certainty remains low regarding the effectiveness of the medication against all potential causative organisms. The increasing documentation of emerging resistance in fungi was observed in some studies, which is an area where research is ongoing, but the long-term consequences are not yet fully established across all global regions.

Key Studies & References

  1. Oral treatments for toenail onychomycosis: a systematic review
  2. Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fed Conditions | ClinicalTrials.gov
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Apo Terbinafine (FAQ)

Q: How long does Apo Terbinafine usually take to show any effect?

A: Terbinafine is described in official product information as highly attracted to fatty tissues and keratin, which causes it to quickly accumulate in the skin and nails. The drug accumulates quickly, but visible improvement in conditions like nail fungus requires many months, as the healthy nail tissue must grow out completely.

Q: Can older adults generally use Apo Terbinafine?

A: Official reports on clinical trials indicate that no differences in the safety or effectiveness of the drug have been identified between older adults and younger patients. Regulatory documents suggest that caution may be appropriate for older adults if pre-existing health conditions, such as kidney or liver issues, are present.

Q: Is it common for people to lose their sense of taste while using Apo Terbinafine?

A: Disturbances to taste, including partial or total taste loss, have been reported during the use of oral terbinafine. While this side effect often resolves after stopping the medication, official safety information indicates that these disturbances can be prolonged or, in rare postmarketing cases, reported as permanent.

Q: Are there different strengths or types of Apo Terbinafine?

A: The oral tablet form is typically available in a single 250 mg strength. The medication also comes in topical (applied to the skin) forms, such as a cream or solution, which are commonly available in a 1% concentration.

Q: Is Apo Terbinafine a prescription-only medicine?

A: The oral tablet form of Apo Terbinafine is classified as a prescription-only medicine in most regions. Conversely, the topical creams and solutions containing the active ingredient, terbinafine, may be available without a prescription depending on the country and condition.

Q: Can a person stop taking Apo Terbinafine once their symptoms improve?

A: Regulatory guidance emphasizes that the required duration should be completed. This approach is intended to help ensure the fungal infection is eliminated and reduce the likelihood of recurrence, even if initial signs of improvement are noted early. The required duration is defined by the site and severity of the infection.

Q: Is Apo Terbinafine effective against all types of fungus?

A: Official information indicates that Apo Terbinafine is fungicidal (kills the fungus) against dermatophytes, which are the most common cause of nail and skin mycoses. The drug's activity against certain yeasts, such as Candida species, may be fungicidal or fungistatic (inhibits growth), depending on the species.

Q: Can people with diabetes use Apo Terbinafine?

A: Official clinical studies have explored the use of the oral tablet in patients with underlying co-existing conditions, including diabetes. Diabetes is not listed in regulatory documents as a formal contraindication or restriction for the use of this medicine.

Q: What is the general timeline for seeing new, healthy nail growth?

A: Clinical studies have shown that the measurement of full clinical clearing of the nail often requires an extended observation period. This process typically extends several months after the full course of medication has been completed, corresponding to the time needed for new, healthy nail tissue to slowly grow out.

Q: What is the most frequently reported side effect in official studies?

A: In clinical trials, the most common adverse reactions reported in official documents include nervous system effects like headache, as well as gastrointestinal effects like diarrhea, nausea, and dyspepsia (indigestion). These are generally reported as Common effects.

Q: Do studies support the long-term use of Apo Terbinafine for nail fungus?

A: Studies track patients for extended periods, sometimes a year or longer, following the completion of treatment to monitor recurrence. However, official regulatory documents state that long-term effects regarding the durability of the initial results beyond the first two years are not fully established.

Q: Are there any common foods or drinks that interact with Apo Terbinafine?

A: The oral tablet form of terbinafine may be taken with or without food, as noted in the official dosing instructions. No major interaction with common food or general beverages is specified in regulatory documents.

Q: Does Apo Terbinafine affect birth control pills?

A: Regulatory advice in some regions recommends cautious use for women taking oral contraceptives, as certain cases of menstrual disorders have been reported with this combination. However, other official information indicates that a clinically relevant interaction may not exist.

Q: How long after stopping Apo Terbinafine do the effects last?

A: The official pharmacokinetic profile indicates that terbinafine is highly lipophilic, meaning it accumulates in tissues like the nails, fat, and skin. Measurable concentrations of the drug can remain present in the affected skin and nail tissue for many weeks to months following the final oral dose.

Q: Does Apo Terbinafine interact with over-the-counter pain relievers?

A: Official sources generally do not indicate any known clinically significant interactions between Apo Terbinafine tablets and common over-the-counter pain relievers, such as ibuprofen or acetaminophen (paracetamol).

Q: Does Apo Terbinafine have any known interactions with herbal supplements?

A: Official drug labeling often states that complementary medicines, herbal remedies, and supplements have not been formally tested for interactions with this drug. Official guidance often highlights the importance of reporting all supplements and herbal remedies to the prescribing healthcare provider.

Q: Does Apo Terbinafine cause changes in mood or sleep?

A: Official postmarketing reports have included instances of depressive symptoms associated with the use of oral terbinafine. Other side effects affecting the nervous system have included insomnia (difficulty sleeping) and unusual dream activity.

Q: Does Apo Terbinafine interact with alcohol?

A: Official warnings on this drug emphasize the potential for serious liver injury (hepatotoxicity). Because both Apo Terbinafine and alcohol are processed by the liver, official guidance suggests avoiding simultaneous use.

Q: Does Apo Terbinafine contain any common allergens?

A: The oral tablet contains the active ingredient, Terbinafine Hydrochloride, plus inactive ingredients (excipients) such as cellulose and silica compounds. Official documents describe that the medicine should not be used by individuals with a known allergy or hypersensitivity to any component of the formulation.

Q: Is Apo Terbinafine considered a first-line treatment for nail fungus?

A: Oral terbinafine is fully approved by regulatory bodies for the treatment of fungal nail infections (onychomycosis). Due to its documented fungicidal activity, it is widely regarded as a primary treatment option for this specific condition.

Q: Can the drug cause photosensitivity or increased sensitivity to the sun?

A: Photosensitivity reactions, which involve unusual skin sensitivity to sunlight, have been reported during postmarketing use of the drug. Regulatory documents include a warning that sun protection measures, such as avoiding excessive UV exposure and using sunscreen, may be necessary while taking this medication.

Advertisements

How should Apo Terbinafine be stored and disposed of?

How to Store and Dispose of Apo Terbinafine Tablets

The storage and disposal of Apo Terbinafine tablets are governed by specific regulatory requirements to ensure product integrity.

Official Storage Requirements

Requirement Condition
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection The tablets must be protected from light and kept in a tightly closed original container.
Child Safety The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Apo Terbinafine must be disposed of in accordance with local requirements. This typically involves returning the unused or damaged product to a pharmacist or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Apo Terbinafine found in:

A-Z Index: